These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 27195659)

  • 1. Emerging antibodies for the treatment of multiple myeloma.
    Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
    Laubach JP; Paba Prada CE; Richardson PG; Longo DL
    Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies - A new era in the treatment of multiple myeloma.
    Jelinek T; Hajek R
    Blood Rev; 2016 Mar; 30(2):101-10. PubMed ID: 26362528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab for the treatment of multiple myeloma.
    Touzeau C; Moreau P
    Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myeloma].
    Nishimura N; Terui Y; Hatake K
    Rinsho Ketsueki; 2017; 58(8):1006-1013. PubMed ID: 28883263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Daratumumab for multiple myeloma].
    Croizier C; Bailly S
    Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
    D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
    Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of daratumumab for the treatment of multiple myeloma.
    Cejalvo MJ; Ribas P; de la Rubia J
    Expert Opin Drug Saf; 2017 Jun; 16(6):753-760. PubMed ID: 28490215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
    Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK
    Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1481-1488. PubMed ID: 30232695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies in myeloma.
    Sondergeld P; van de Donk NW; Richardson PG; Plesner T
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):599-609. PubMed ID: 26452191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses.
    Musto P; La Rocca F
    Expert Rev Hematol; 2020 Apr; 13(4):331-349. PubMed ID: 32153224
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging immune targets for the treatment of multiple myeloma.
    Sohail A; Mushtaq A; Iftikhar A; Warraich Z; Kurtin SE; Tenneti P; McBride A; Anwer F
    Immunotherapy; 2018 Feb; 10(4):265-282. PubMed ID: 29421983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
    Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
    Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
    [No Abstract]   [Full Text] [Related]  

  • 19. Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.
    Eleutherakis-Papaiakovou E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Kastritis E; Terpos E; Dimopoulos MA
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):921-928. PubMed ID: 31679403
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
    Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
    Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.